Evidence-Based Medicine for Student Health Services
Robert J. Flaherty, MD
Swingle Student Health Service
Montana State University
Bozeman, MT 59717
Acute Bronchitis
 
Etiology Monitoring
Epidemiology Prognosis
Diagnosis Prevention
Treatment Patient Education
   
 
General Information
   
EBM for Student Health  
    Home Page  
   
About EBM  
  
EBM Resources 
 
Specific Conditions/Diseases
  
  
 
   
Etiology 
Acute bronchitis is rarely caused by atypical bacteria such as C. pneumoniae and M. pneumoniae, and rarely caused by bacterial infections severe enough significantly to increase the level of C-reactive protein.    
Epidemiology 
No evidence is cited. 
  
Diagnosis 
Of patients presenting with chronic cough, 92% had gastroesophageal reflux disease (GERD), postnasal drip syndrome, and/or asthma. Considering only patients with cough of at least 3 weeks duration who are non-smokers, are not receiving angiotensin-converting enzyme (ACE) inhibitors, and have normal or nearly normal and stable chest radiographs, 99.4% will have GERD, postnasal drip syndrome, and/or asthma. Only 39% had a single cause of cough.   
Treatment  
Antibiotics 
Doxycycline, erythromycin and trimethoprim/sulfamethoxazole appear to have, at best, a modest beneficial effect in the treatment of acute bronchitis, with a corresponding small risk of adverse effects. Antibiotic treated groups tended to be either no less likely or slightly less likely to report feeling unwell at a follow up visit, to show no improvement on physician assessment or to have abnormal lung findings, and had a more rapid return to work or usual activities. Antibiotic- treated patients reported significantly more adverse effects such as nausea, vomiting, headache, skin rash or vaginitis.  Cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten were compared to conventional antibiotic therapies (usually amoxicillin/clavulanate, cefaclor or cephalexin) for community acquired infections. Infections included acute otitis media, pharyngitis, sinusitis, bronchitis, pneumonia, urinary tract infection and skin and skin-structure infections. The newer agents appear to be as clinically effective as conventional therapies (but not more effective) for the treatment of common community-acquired infections. They may also have the potential to improve compliance due to their once/twice daily mode of
administration. 
  • Caveats
    • Age group studied: Unknown
    • Type/size: Analytical review of studies: acute otitis media: 19 studies, pharyngitis: 13 studies, sinusitis: 4 studies, bronchitis: 10 studies, pneumonia: 7 studies, urinary tract infection: 11 studies, skin and skin-structure infections: 4 studies. Most studies consisted of 30-50 patients in each arm
    • Population: Unknown
    • Outcome measure: Clinical response to therapy
    • For some of these infections other studies show that there is no evidence that any antibiotic therapy is beneficial
  • Citations
Under most circumstances, the most cost-effective strategy for treating acute bronchitis is to withhold antibiotics and treat only patients whose cough does not resolve.  Receiving a prescription for an antibiotic for a URI was not associated with increased patient satisfaction. Better to spend time explaining the nature of a particular illness and the physician's choice of treatment. Bronchodilators 
There is a modest benefit from inhaled (preferred) or liquid albuterol, in terms of reduced duration of cough and a quicker return to work, particularly in patients with purulent secretions.     
Monitoring
No evidence is cited.
 
Prognosis     
Informational handouts which describe the purpose and natural history of coughs can lower the rate of return visits for lower respiratory tract symptoms.    
Prevention 
No evidence is cited.  
 
Patient Education
The following patient education materials are consistent with the available evidence.
 Rev. 7/11/01

This Web site developed and maintained by Robert J. Flaherty, MD.
Comments, additions and corrections are encouraged.